JPWO2014128882A1 - 不安うつ病の治療薬 - Google Patents
不安うつ病の治療薬 Download PDFInfo
- Publication number
- JPWO2014128882A1 JPWO2014128882A1 JP2015501155A JP2015501155A JPWO2014128882A1 JP WO2014128882 A1 JPWO2014128882 A1 JP WO2014128882A1 JP 2015501155 A JP2015501155 A JP 2015501155A JP 2015501155 A JP2015501155 A JP 2015501155A JP WO2014128882 A1 JPWO2014128882 A1 JP WO2014128882A1
- Authority
- JP
- Japan
- Prior art keywords
- depression
- action
- anxiety
- medicament
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000020401 Depressive disease Diseases 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims description 54
- 229940079593 drug Drugs 0.000 title claims description 15
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 49
- 230000036506 anxiety Effects 0.000 claims abstract description 40
- 230000003001 depressive effect Effects 0.000 claims abstract description 37
- 230000009471 action Effects 0.000 claims abstract description 33
- 230000001149 cognitive effect Effects 0.000 claims abstract description 27
- 230000008451 emotion Effects 0.000 claims abstract description 27
- 229950004193 perospirone Drugs 0.000 claims abstract description 27
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 102000005962 receptors Human genes 0.000 claims abstract description 14
- 108020003175 receptors Proteins 0.000 claims abstract description 14
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims abstract description 13
- 239000003420 antiserotonin agent Substances 0.000 claims abstract description 13
- 229960002748 norepinephrine Drugs 0.000 claims abstract description 13
- 230000000794 anti-serotonin Effects 0.000 claims abstract description 9
- 239000004031 partial agonist Substances 0.000 claims abstract description 9
- 230000002973 anti-dopamine Effects 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 102000017911 HTR1A Human genes 0.000 claims abstract description 4
- 208000025748 atypical depressive disease Diseases 0.000 claims description 32
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 21
- 206010041250 Social phobia Diseases 0.000 claims description 19
- 208000019906 panic disease Diseases 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 7
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims description 7
- 206010001540 Akathisia Diseases 0.000 claims description 6
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 6
- 229940124811 psychiatric drug Drugs 0.000 claims description 6
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 5
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 5
- 229940049706 benzodiazepine Drugs 0.000 claims description 5
- 229960001432 lurasidone Drugs 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 abstract description 14
- -1 perospirone Chemical class 0.000 abstract description 3
- 150000003413 spiro compounds Chemical class 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 25
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 18
- 206010020751 Hypersensitivity Diseases 0.000 description 11
- 208000026935 allergic disease Diseases 0.000 description 11
- 230000009610 hypersensitivity Effects 0.000 description 11
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000000707 wrist Anatomy 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 9
- 230000006872 improvement Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 6
- 108091005479 5-HT2 receptors Proteins 0.000 description 6
- 206010016754 Flashback Diseases 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 101150049660 DRD2 gene Proteins 0.000 description 5
- 239000002981 blocking agent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 229960001534 risperidone Drugs 0.000 description 5
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 5
- 102000035038 5-HT1 receptors Human genes 0.000 description 4
- 108091005478 5-HT1 receptors Proteins 0.000 description 4
- 208000019022 Mood disease Diseases 0.000 description 4
- 206010034912 Phobia Diseases 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000002442 prefrontal cortex Anatomy 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 3
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 3
- 206010020710 Hyperphagia Diseases 0.000 description 3
- 206010033664 Panic attack Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001090 anti-dopaminergic effect Effects 0.000 description 3
- 239000000939 antiparkinson agent Substances 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 229960004372 aripiprazole Drugs 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229960004391 lorazepam Drugs 0.000 description 3
- 229960002863 lurasidone hydrochloride Drugs 0.000 description 3
- NEKCRUIRPWNMLK-SCIYSFAVSA-N lurasidone hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 NEKCRUIRPWNMLK-SCIYSFAVSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 235000020830 overeating Nutrition 0.000 description 3
- 208000022821 personality disease Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000019899 phobic disease Diseases 0.000 description 3
- 229960004431 quetiapine Drugs 0.000 description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000013200 Stress disease Diseases 0.000 description 2
- 208000012981 Traumatic Stress disease Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000026345 acute stress disease Diseases 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- RDNLAULGBSQZMP-UHFFFAOYSA-N biperiden hydrochloride Chemical compound [Cl-].C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CC[NH+]1CCCCC1 RDNLAULGBSQZMP-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 2
- 229940042053 methotrimeprazine Drugs 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QDWJJTJNXAKQKD-UHFFFAOYSA-N trihexyphenidyl hydrochloride Chemical compound Cl.C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 QDWJJTJNXAKQKD-UHFFFAOYSA-N 0.000 description 2
- WQRPHHIOZYGAMQ-UHFFFAOYSA-N 3-methyl-n-phenylbutanamide Chemical compound CC(C)CC(=O)NC1=CC=CC=C1 WQRPHHIOZYGAMQ-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 108091007265 Dopamine D2-Like Receptors Proteins 0.000 description 1
- 101710107142 Dopamine receptor 2 Proteins 0.000 description 1
- 241000919496 Erysimum Species 0.000 description 1
- 206010073753 Fear of injection Diseases 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- 241000691979 Halcyon Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 208000000810 Separation Anxiety Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229960000749 biperiden hydrochloride Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000002898 effect on depression Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000008434 fear extinction Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940036674 latuda Drugs 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000025319 neurotic depression Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000025874 separation anxiety disease Diseases 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960004479 trihexyphenidyl hydrochloride Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2013/054344 WO2014128882A1 (fr) | 2013-02-21 | 2013-02-21 | Agent thérapeutique pour la dépression anxieuse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2014128882A1 true JPWO2014128882A1 (ja) | 2017-02-02 |
Family
ID=51390712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501155A Pending JPWO2014128882A1 (ja) | 2013-02-21 | 2013-02-21 | 不安うつ病の治療薬 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2014128882A1 (fr) |
| WO (1) | WO2014128882A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002308801A (ja) * | 2001-03-01 | 2002-10-23 | Pfizer Prod Inc | うつ病、強迫疾患および精神病の組み合わせ治療 |
| JP2003532621A (ja) * | 1999-04-09 | 2003-11-05 | タイタン ファーマシューティカルズ， インコーポレイテッド | 精神分裂病の処置方法 |
| JP2009509959A (ja) * | 2005-09-23 | 2009-03-12 | シェーリング コーポレイション | ７−［２−［４−（６−フルオロ−３−メチル−１，２−ベンズイソキサゾール−５−イル）−１−ピペラジニル］エチル］−２−（１−プロピニル）−７Ｈ−ピラゾロ−［４，３−ｅ］−［１，２，４］−トリアゾロ−［１，５−ｃ］−ピリミジン−５−アミン |
| JP2010510314A (ja) * | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス，エルエルシー | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100054812A (ko) * | 2007-08-01 | 2010-05-25 | 메디베이션 뉴롤로지 인코퍼레이티드 | 항정신병제 조합 치료제를 사용하여 정신분열증을 치료하기 위한 방법 및 조성물 |
-
2013
- 2013-02-21 WO PCT/JP2013/054344 patent/WO2014128882A1/fr active Application Filing
- 2013-02-21 JP JP2015501155A patent/JPWO2014128882A1/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003532621A (ja) * | 1999-04-09 | 2003-11-05 | タイタン ファーマシューティカルズ， インコーポレイテッド | 精神分裂病の処置方法 |
| JP2002308801A (ja) * | 2001-03-01 | 2002-10-23 | Pfizer Prod Inc | うつ病、強迫疾患および精神病の組み合わせ治療 |
| JP2009509959A (ja) * | 2005-09-23 | 2009-03-12 | シェーリング コーポレイション | ７−［２−［４−（６−フルオロ−３−メチル−１，２−ベンズイソキサゾール−５−イル）−１−ピペラジニル］エチル］−２−（１−プロピニル）−７Ｈ−ピラゾロ−［４，３−ｅ］−［１，２，４］−トリアゾロ−［１，５−ｃ］−ピリミジン−５−アミン |
| JP2010510314A (ja) * | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス，エルエルシー | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014128882A1 (fr) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021202433C1 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP6462663B2 (ja) | 心的外傷後ストレス障害を処置するための方法 | |
| Huntington Study Group HART Investigators | A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease | |
| IL261658B2 (en) | Neuroactive steroids, preparations and their uses | |
| Paik et al. | Amantadine extended-release (GOCOVRI™): a review in levodopa-induced dyskinesia in Parkinson’s disease | |
| Roberts et al. | A randomized, controlled study comparing the effects of vestipitant or vestipitant and paroxetine combination in subjects with tinnitus | |
| CA3176234A1 (fr) | Procedes de traitement de l'agitation associee a la maladie d'alzheimer | |
| US20230000799A1 (en) | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy | |
| WO2014128882A1 (fr) | Agent thérapeutique pour la dépression anxieuse | |
| DK2694065T3 (en) | COMPOSITION FOR TREATMENT OF DISORDER WITH SEXUAL SEXUAL LISTENING | |
| KR20020086911A (ko) | 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도 | |
| Chechani | Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy | |
| CA3209781A1 (fr) | Utilisation de luvadaxistat pour le traitement d'une deficience cognitive | |
| US20230131493A1 (en) | Methods of treating agitation associated with alzheimer's disease | |
| TWI233354B (en) | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders | |
| Loughlin et al. | The guide to off-label prescription drugs: new uses for FDA-approved prescription drugs | |
| Akpalu Jr et al. | Amodiaquine-induced dystonic reactions: case reports and implications for policy change in Ghana | |
| Hazra | A comparative study on the pharmacovigilance scoring of causality assessment grading and staging of topical pharmacotherapy of ofloxacin 0.3% ophthalmic solution in bacterial conjunctivitis and ofloxacin 0.3% otic solution in otitis externa | |
| KR20240110812A (ko) | 알츠하이머병과 관련된 불안을 치료하는 방법 | |
| AU2022409230A1 (en) | Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression | |
| AU2022387053A1 (en) | Treatment of treatment resistant depression with psilocybin | |
| TW201106944A (en) | Exo-S-mecamylamine method, use, and compound for treatment | |
| CN117580576A (zh) | Luvadaxistat用于治疗认知损害的用途 | |
| NZ785712A (en) | Neuroactive steroids, compositions, and uses thereof | |
| Loughlin et al. | Prescription drugs: Alternative uses, alternative cures: over 1,500 new uses for FDA-approved drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170404 |